News

Filter

1 to 9 of 22 results

Non-small cell lung cancer pipeline shows shift away from traditional chemotherapies, says GBI Research

Non-small cell lung cancer pipeline shows shift away from traditional chemotherapies, says GBI Research

05-11-2014

There is cause for optimism in the non-small cell lung cancer (NSCLC) treatment pipeline, according to…

BiotechnologyGBI ResearchHealth Medical PharmaOncologyResearch

Amgen files for EU approval of talimogene laherparepvec and for evolocumab

Amgen files for EU approval of talimogene laherparepvec and for evolocumab

02-09-2014

Leading independent biotech firm Amgen has submitted a Marketing Authorization Application to the European…

AmgenBiotechnologyCardio-vascularEuropeevolocumabFamilial hypercholesterolemiaHealthHealth Medical PharmaHealth Medical PharmaOncologyPCSK9Regulationtalimogene laherparepvec

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

15-07-2014

In an interview with The Pharma Letter, Nicholas Saccomano, chief science officer of Array BioPharma,…

Array BioPharmaBiogen IdecBiotechnologyChief science officerHealth Medical PharmaInterviewsMelanomaOncologyProtein kinase inhibitorUSA

Merck & Co returns rights to Endocyte’s vintafolide

Merck & Co returns rights to Endocyte’s vintafolide

18-06-2014

Shares of USA-based Endocyte fell 19.7% to $6.20 in after-hours trading yesterday, after the company…

CisplatinEnd point of clinical trialsEndocyteHealth Medical PharmaLicensingMerck & CoOncologyPEGylationPharmaceuticalPlatinum-resistant ovarian cancervintafolide

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial

12-06-2014

US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

1 to 9 of 22 results

Back to top